A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 834 participants.
Also called NCT03235050
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 834 participants
- Sponsor
- Registry
-
NCT03235050
-
- Other papers using this trial's data
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Czechia, Germany, Mexico, Russia, Slovakia
- Registry status
- Completed
Technical summary
Registry record NCT03235050. Randomized; triple masking; primary purpose treatment. Start 2017-08-02 (actual); primary completion 2018-05-03 (actual). Results posted on 2020-07-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- MEDI0382 low dose
- Intervention (Drug)
- MEDI0382 mid dose
- Intervention (Drug)
- MEDI0382 high dose
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Liraglutide
- Lead sponsor
- AstraZeneca
- Collaborator
- MedImmune LLC
Record details
- Record id
cardio:ct-nct03235050- Content hash
45d7691987cc17ca131cb7c82b6ef896a15a25273711d2f4eea0b4268769e53c